Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? From Chinese healthcare system perspective

Yuting Wang and Gang Huang
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 480;
Yuting Wang
1Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Huang
1Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

480

Objectives To assess the cost-effectiveness of FDG PET/CT in patients with potentially operative non-small cell lung cancer (NSCLC) in China.

Methods Management of NSCLC was modeled on decision analysis employing data in China. The strategies compared were conventional CT staging (strategy A), additional fluorodeoxyglucose positron emission tomography (FDG PET)/CT in all patients (strategy B) or only in patients with normal-sized lymph nodes on CT (strategy C). Published data including accuracies for detecting mediastinal lymph nodes for PET/CT and CT in China was extracted. The costs quoted corresponded to reimbursement in 2010 by the public health provider and followed the official guidelines for medical practice in China. Uncertainly of employed parameters were taken into account in sensitivity analysis.

Results Taking strategy A as baseline, the incremental cost-effectiveness ratio (ICER) of strategy B was 23,800 RMB(3500 dollars) per life year saved, within the commonly accepted range; while strategy C exhibited some loss of life years overall. Sensitivity analysis suggested the ICER (B-A) was more sensitive to a hypothetical deterioration of PET specificity than to its sensitivity. The ICER was turned negative by PET specificity lower than 0.79. Economically, a 20% raise of PET cost still led to an ICER within acceptable range (31,800 RMB/LYS), and decrease of palliative therapy cost, which was relatively high in China, could contribute to reduction of both ICER and overall cost per patient.

Conclusions This decision analysis modeling indicated the potential cost-effectiveness of the PET/CT strategy for management of NSCLC in China, with an acceptable ICER. Patients with nodal-positive CT results are not suggested to be excluded from further exams as PET/CT. Furthermore, maintaining high specificity of PET in clinical scenarios is crucial. Prospective studies are warranted to transfer these results into policy making.

Research Support National Natural Science Foundation of China, Project Number: 30830038, 81071180, 30970842; Shanghai Leading Academic Discipline Project, Project Number: S3020

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? From Chinese healthcare system perspective
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? From Chinese healthcare system perspective
Yuting Wang, Gang Huang
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 480;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? From Chinese healthcare system perspective
Yuting Wang, Gang Huang
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 480;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • Renal scintigraphy following kidney transplantation – ATN, Rejection, and More
  • Assessing global coronary artery disease with NaF-PET/CT: Introducing the Alavi-Carlsen Calcification Score (ACCS)
  • Evolving role of FDG-PET/CT in the workup of infective endocarditis
Show more General Clinical Specialties

Outcomes/Comparative Effectiveness Research

  • A new complex diagnostic protocol for the diagnosis of nasolacrimal duct obstruction: Simultaneous dacryocystography and dacryoscintigraphy using SPECT/CT
  • A systematic literature review of clinical comparative effectiveness and cost-effectiveness evidence for PET in oncology
Show more Outcomes/Comparative Effectiveness Research

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire